Innate Pharma SA files 20-F

Innate Pharma SA reported a net loss of €49.2 million for the fiscal year ended December 31, 2025, compared to a net loss of €49.5 million in 2024, with its cash, cash equivalents, and short-term investments decreasing to €34.3 million, which is estimated to fund operations only until the end of the third quarter of 2026. The company is actively pursuing additional financing, including non-dilutive options, to support its continued operations and development of its prioritized clinical assets. (2) Key points from the filing: